| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Research Abstract |
Genome-wide methylation analysis of over 100 gliomas including matched-pairs of initial low-grade gliomas and recurrent tumors identified CpG island methylator phenotype (CIMP). Remarkably, approximately 50% of secondary glioblastomas that had progressed from low-grade tumors with the CIMP status exhibited a characteristic partial demethylation of genomic DNA during malignant progression. Demethylation might be one mechanism of malignant progression. Specifically, we identified demethylation and upregulation of IGFBP2 after malignant progression of low grade gliomas. IGFBP2 methylation was prognostic factor of malignantly progressed gliomas, and could be used as a methylation marker and a therapeutic target.
|
